Publications
Detailed Information
Efficacy of Rifaximin Compared with Ciprofloxacin for the Treatment of Acute Infectious Diarrhea: A Randomized Controlled Multicenter Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Kyoung Sup | - |
dc.contributor.author | Kim, You Sun | - |
dc.contributor.author | Han, Dong Soo | - |
dc.contributor.author | Choi, Chang Hwan | - |
dc.contributor.author | Park, Young-Sook | - |
dc.contributor.author | Lee, Soo Teik | - |
dc.contributor.author | Kim, Joo Sung | - |
dc.contributor.author | Kim, Hyun-Soo | - |
dc.contributor.author | Lee, Kang-Moon | - |
dc.contributor.author | Jang, Byung-Ik | - |
dc.date.accessioned | 2012-06-27T06:14:10Z | - |
dc.date.available | 2012-06-27T06:14:10Z | - |
dc.date.issued | 2010-09-30 | - |
dc.identifier.citation | GUT AND LIVER; Vol.4 3; 357-362 | ko_KR |
dc.identifier.issn | 1976-2283 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77599 | - |
dc.description.abstract | Background/Aims: Ciprofloxacin has been widely prescribed for acute infectious diarrhea. However, the resistance to this drug is increasing. Rifaximin is a novel but poorly absorbed rifamycin derivative. This study evaluated and compared the efficacies of rifaximin and ciprofloxacin for the treatment of acute infectious diarrhea. Methods: We performed a randomized controlled multicenter study in Korea. Patients with acute diarrhea were enrolled and randomized to receive rifaximin or ciprofloxacin for 3 days. The primary efficacy endpoint was the time to last unformed stool (TLUS). Secondary endpoints were enteric wellness (reduction of at least 50% in the number of unformed stools during 24-hour postenrollment intervals), general wellness (subjective feeling of improvement), and proportion of patients with treatment failure. Results: Intent-to-treat analysis (n=143) showed no significant difference between the rifaximin and ciprofloxacin groups in the mean TLUS (36.1 hours vs 43.6 hours, p=0.163), enteric wellness (49% vs 57%, p=0.428), general wellness (67% vs 78%, p=0.189), or treatment failure rate (9% vs 12%, p=0.841). The adverse events did not differ significantly between the two groups. Conclusions: These results suggest that rifaximin is as safe and effective as ciprofloxacin in the treatment of acute infectious diarrhea. (Gut Liver 2010;4:357-362) | ko_KR |
dc.description.sponsorship | This study was supported by the research fund of the Korean Association for the Study of Intestinal Diseases. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | EDITORIAL OFFICE GUT & LIVER | ko_KR |
dc.subject | Acute infectious diarrhea | ko_KR |
dc.subject | Ciprofloxacin | ko_KR |
dc.subject | Rifaximin | ko_KR |
dc.title | Efficacy of Rifaximin Compared with Ciprofloxacin for the Treatment of Acute Infectious Diarrhea: A Randomized Controlled Multicenter Study | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 홍경섭 | - |
dc.contributor.AlternativeAuthor | 김유선 | - |
dc.contributor.AlternativeAuthor | 한동수 | - |
dc.contributor.AlternativeAuthor | 최창환 | - |
dc.contributor.AlternativeAuthor | 장병익 | - |
dc.contributor.AlternativeAuthor | 박영숙 | - |
dc.contributor.AlternativeAuthor | 이강문 | - |
dc.contributor.AlternativeAuthor | 이수택 | - |
dc.contributor.AlternativeAuthor | 김현수 | - |
dc.contributor.AlternativeAuthor | 김주성 | - |
dc.identifier.doi | 10.5009/gnl.2010.4.3.357 | - |
dc.citation.journaltitle | GUT AND LIVER | - |
dc.description.citedreference | KIM EC, 2009, SEOUL NATL U HOSP IN, V15, P5 | - |
dc.description.citedreference | Yang JR, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-151 | - |
dc.description.citedreference | Cho SH, 2008, J MICROBIOL, V46, P325, DOI 10.1007/s12275-008-0015-4 | - |
dc.description.citedreference | Taylor DN, 2006, AM J TROP MED HYG, V74, P1060 | - |
dc.description.citedreference | Adachi JA, 2006, CLIN INFECT DIS, V42, P541 | - |
dc.description.citedreference | Robins GW, 2005, DRUGS, V65, P1697 | - |
dc.description.citedreference | Lee K, 2004, YONSEI MED J, V45, P598 | - |
dc.description.citedreference | Martini S, 2004, BIOORGAN MED CHEM, V12, P2163, DOI 10.1016/j.bmc.2004.02.027 | - |
dc.description.citedreference | *SAL PHARM, 2004, XIF RIF TABL | - |
dc.description.citedreference | Lautcnbach E, 2002, ARCH INTERN MED, V162, P2469 | - |
dc.description.citedreference | Brigidi P, 2002, J CHEMOTHERAPY, V14, P290 | - |
dc.description.citedreference | DuPont HL, 2001, CLIN INFECT DIS, V33, P1807, DOI 10.1086/323814 | - |
dc.description.citedreference | Cheong HJ, 2001, CLIN INFECT DIS, V33, P48 | - |
dc.description.citedreference | Guerrant RL, 2001, CLIN INFECT DIS, V32, P331, DOI 10.1086/318514 | - |
dc.description.citedreference | Jiang ZD, 2000, ANTIMICROB AGENTS CH, V44, P2205 | - |
dc.description.citedreference | Smith KE, 1999, NEW ENGL J MED, V340, P1525, DOI 10.1056/NEJM199905203402001 | - |
dc.description.citedreference | Steffen R, 1999, JAMA-J AM MED ASSOC, V281, P811 | - |
dc.description.citedreference | Chong Y, 1998, YONSEI MED J, V39, P569 | - |
dc.description.citedreference | Ena J, 1998, DIAGN MICR INFEC DIS, V30, P103 | - |
dc.description.citedreference | PENA C, 1995, ANTIMICROB AGENTS CH, V39, P520 | - |
dc.description.citedreference | DESCOMBE JJ, 1994, INT J CLIN PHARM RES, V14, P51 | - |
dc.description.citedreference | DELEO C, 1986, DRUG EXP CLIN RES, V12, P979 | - |
dc.description.tc | 0 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.